159 related articles for article (PubMed ID: 34123574)
1. Priming of pancreatic cancer cells with bispecific antibody armed activated T cells sensitizes tumors for enhanced chemoresponsiveness.
Thakur A; Ung J; Tomaszewski EN; Schienschang A; LaBrie TM; Schalk DL; Lum LG
Oncoimmunology; 2021 Jun; 10(1):1930883. PubMed ID: 34123574
[TBL] [Abstract][Full Text] [Related]
2. Clinical and immune responses to anti-CD3 x anti-EGFR bispecific antibody armed activated T cells (EGFR BATs) in pancreatic cancer patients.
Lum LG; Thakur A; Choi M; Deol A; Kondadasula V; Schalk D; Fields K; Dufrense M; Philip P; Dyson G; Aon HD; Shields AF
Oncoimmunology; 2020 Jun; 9(1):1773201. PubMed ID: 32939319
[TBL] [Abstract][Full Text] [Related]
3. Broad reactivity and enhanced potency of recombinant anti-EGFR × anti-CD3 bispecific antibody-armed activated T cells against solid tumours.
Huang MTF; Sharma V; Mendelsohn A; Wei Q; Li J; Yu B; Larrick JW; Lum LG
Ann Med; 2022 Dec; 54(1):1047-1057. PubMed ID: 36799362
[No Abstract] [Full Text] [Related]
4. Phase II clinical trial using anti-CD3 × anti-HER2 bispecific antibody armed activated T cells (HER2 BATs) consolidation therapy for HER2 negative (0-2+) metastatic breast cancer.
Lum LG; Al-Kadhimi Z; Deol A; Kondadasula V; Schalk D; Tomashewski E; Steele P; Fields K; Giroux M; Liu Q; Flaherty L; Simon M; Thakur A
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34117114
[TBL] [Abstract][Full Text] [Related]
5. An epithelial cell adhesion molecule- and CD3-bispecific antibody plus activated T-cells can eradicate chemoresistant cancer stem-like pancreatic carcinoma cells in vitro.
Umebayashi M; Kiyota A; Koya N; Tanaka H; Onishi H; Katano M; Morisaki T
Anticancer Res; 2014 Aug; 34(8):4509-19. PubMed ID: 25075094
[TBL] [Abstract][Full Text] [Related]
6. Solitomab, an epithelial cell adhesion molecule/CD3 bispecific antibody (BiTE), is highly active against primary chemotherapy-resistant ovarian cancer cell lines in vitro and fresh tumor cells ex vivo.
English DP; Bellone S; Schwab CL; Roque DM; Lopez S; Bortolomai I; Cocco E; Bonazzoli E; Chatterjee S; Ratner E; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Santin AD
Cancer; 2015 Feb; 121(3):403-12. PubMed ID: 25251053
[TBL] [Abstract][Full Text] [Related]
7. Enhanced cytotoxicity against solid tumors by bispecific antibody-armed CD19 CAR T cells: a proof-of-concept study.
Thakur A; Scholler J; Schalk DL; June CH; Lum LG
J Cancer Res Clin Oncol; 2020 Aug; 146(8):2007-2016. PubMed ID: 32449004
[TBL] [Abstract][Full Text] [Related]
8. LIGHT enhanced bispecific antibody armed T-cells to treat immunotherapy resistant colon cancer.
Qiao G; Kone LB; Phillips EH; Lee SS; Brown GE; Khetani SR; Thakur A; Lum LG; Prabhakar BS; Maker AV
Oncogene; 2022 Apr; 41(14):2054-2068. PubMed ID: 35177811
[TBL] [Abstract][Full Text] [Related]
9. EpCAM/CD3-Bispecific T-cell engaging antibody MT110 eliminates primary human pancreatic cancer stem cells.
Cioffi M; Dorado J; Baeuerle PA; Heeschen C
Clin Cancer Res; 2012 Jan; 18(2):465-74. PubMed ID: 22096026
[TBL] [Abstract][Full Text] [Related]
10. Anti-CD3 x anti-epidermal growth factor receptor (EGFR) bispecific antibody redirects T-cell cytolytic activity to EGFR-positive cancers in vitro and in an animal model.
Reusch U; Sundaram M; Davol PA; Olson SD; Davis JB; Demel K; Nissim J; Rathore R; Liu PY; Lum LG
Clin Cancer Res; 2006 Jan; 12(1):183-90. PubMed ID: 16397041
[TBL] [Abstract][Full Text] [Related]
11. Targeting immunotherapy for bladder cancer using anti-CD3× B7-H3 bispecific antibody.
Ma W; Ma J; Ma P; Lei T; Zhao M; Zhang M
Cancer Med; 2018 Oct; 7(10):5167-5177. PubMed ID: 30253078
[TBL] [Abstract][Full Text] [Related]
12. Anti-CS1 × Anti-CD3 Bispecific Antibody (BiAb)-Armed Anti-CD3 Activated T Cells (CS1-BATs) Kill CS1
Lum LG; Thakur A; Elhakiem A; Alameer L; Dinning E; Huang M
Front Oncol; 2020; 10():544. PubMed ID: 32432032
[No Abstract] [Full Text] [Related]
13. Bispecific Antibody Armed Metabolically Enhanced Headless CAR T Cells.
Thakur A; Scholler J; Kubicka E; Bliemeister ET; Schalk DL; June CH; Lum LG
Front Immunol; 2021; 12():690437. PubMed ID: 34290709
[TBL] [Abstract][Full Text] [Related]
14. Anti-CD3 x anti-HER2 bispecific antibody effectively redirects armed T cells to inhibit tumor development and growth in hormone-refractory prostate cancer-bearing severe combined immunodeficient beige mice.
Davol PA; Smith JA; Kouttab N; Elfenbein GJ; Lum LG
Clin Prostate Cancer; 2004 Sep; 3(2):112-21. PubMed ID: 15479495
[TBL] [Abstract][Full Text] [Related]
15. T cells armed with anti-CD3 x anti-CD20 bispecific antibody enhance killing of CD20+ malignant B cells and bypass complement-mediated rituximab resistance in vitro.
Gall JM; Davol PA; Grabert RC; Deaver M; Lum LG
Exp Hematol; 2005 Apr; 33(4):452-9. PubMed ID: 15781336
[TBL] [Abstract][Full Text] [Related]
16. Targeting and killing of glioblastoma with activated T cells armed with bispecific antibodies.
Zitron IM; Thakur A; Norkina O; Barger GR; Lum LG; Mittal S
BMC Cancer; 2013 Feb; 13():83. PubMed ID: 23433400
[TBL] [Abstract][Full Text] [Related]
17. Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE), is highly active against primary uterine serous papillary carcinoma cell lines in vitro.
Bellone S; Black J; English DP; Schwab CL; Lopez S; Cocco E; Bonazzoli E; Predolini F; Ferrari F; Ratner E; Silasi DA; Azodi M; Schwartz PE; Santin AD
Am J Obstet Gynecol; 2016 Jan; 214(1):99.e1-8. PubMed ID: 26272866
[TBL] [Abstract][Full Text] [Related]
18. Activated T cells from umbilical cord blood armed with anti-CD3 × anti-CD20 bispecific antibody mediate specific cytotoxicity against CD20+ targets with minimal allogeneic reactivity: a strategy for providing antitumor effects after cord blood transplants.
Thakur A; Sorenson C; Norkina O; Schalk D; Ratanatharathorn V; Lum LG
Transfusion; 2012 Jan; 52(1):63-75. PubMed ID: 21745212
[TBL] [Abstract][Full Text] [Related]
19. Ipilimumab augments antitumor activity of bispecific antibody-armed T cells.
Yano H; Thakur A; Tomaszewski EN; Choi M; Deol A; Lum LG
J Transl Med; 2014 Jul; 12():191. PubMed ID: 25008236
[TBL] [Abstract][Full Text] [Related]
20. Pan-Bcl-2 inhibitor AT-101 enhances tumor cell killing by EGFR targeted T cells.
Thakur A; Lum LG; Schalk D; Azmi A; Banerjee S; Sarkar FH; Mohommad R
PLoS One; 2012; 7(11):e47520. PubMed ID: 23185240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
